nach oben

Annals of Hematology

Erschienen in:

08.01.2021 | Original Article

Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis

verfasst von: Feiqiong Gao, Jiawei Zhang, Jianlai Hu, Liming Lin, Yang Xu

Erschienen in: Annals of Hematology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Graft-versus-host disease (GVHD) prophylaxis based on post-transplant cyclophosphamide (PTCy) or antithymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantations (allo-HCT). The differential impacts of PTCy and ATG on transplantation outcomes are not well characterized. Here we report a meta-analysis of PTCy versus ATG in allo-HCT. Ten studies were eligible, and a total of 1871 patients were included. The incidence of II-IV aGVHD, III-IV aGVHD, and NRM were significantly lower in PTCy arm (HR = 0.63, 95% CI 0.45–0.89; HR = 0.35, 95% CI 0.16–0.77; HR = 0.59, 95% CI 0.48–0.73). PTCy was associated with a better OS and PFS (HR = 0.62, 95% CI = 0.53–0.73; HR = 0.76, 95% CI 0.62–0.93). The relapse rate and cGVHD incidence were not significantly different between PTCy and ATG (HR = 0.85, 95% CI 0.68–1.07; HR = 0.65, 95% CI 0.38–1.12). Thus, compared with ATG, PTCy has a better aGVHD control and OS benefit, without increasing relapse risk, which needs further validation in prospective randomized trials.

Nur mit Berechtigung zugänglich

McCurdy SR, Kasamon YL, Kanakry CG, Bolanos-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L (2017) Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 102(2):391–400. https://doi.org/10.3324/haematol.2016.144139CrossRefPubMedPubMedCentral

Zeiser R (2018) Biology-driven developments in the therapy of acute graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2018(1):236–241. https://doi.org/10.1182/asheducation-2018.1.236CrossRefPubMedPubMedCentral

Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA (2016) Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy 8(4):435–447. https://doi.org/10.2217/imt.15.128CrossRefPubMed

Metheny L, de Lima M (2018) Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis. Expert Rev Hematol 12(1):47–60. https://doi.org/10.1080/17474086.2019.1562331CrossRefPubMed

Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO (2018) Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601–606. https://doi.org/10.1038/s41409-018-0367-2CrossRefPubMedPubMedCentral

Ross D, Jones M, Komanduri K, Levy RB (2013) Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 19(10):1430–1438. https://doi.org/10.1016/j.bbmt.2013.06.019CrossRefPubMedPubMedCentral

Poonsombudlert K, Kewcharoen J, Prueksapraopong C, Limpruttidham N (2019) Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis. Jpn J Clin Oncol 49(10):924–931. https://doi.org/10.1093/jjco/hyz099CrossRefPubMed

El Fakih R, Hashmi SK, Ciurea SO, Luznik L, Gale RP, Aljurf M (2019) Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant 55(1):40–47. https://doi.org/10.1038/s41409-019-0547-8CrossRefPubMed

Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA (2019) Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant 54(7):1094–1106. https://doi.org/10.1038/s41409-018-0393-0CrossRefPubMed

10.

Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE (2012) Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1835–1844. https://doi.org/10.1016/j.bbmt.2012.07.003CrossRefPubMedPubMedCentral

11.

Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gulbas Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y, Tischer J, Santarone S, Giebel S, Mohty M, Nagler A (2017) Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol 10(1):113. https://doi.org/10.1186/s13045-017-0480-5CrossRefPubMedPubMedCentral

12.

Metafuni E, Chiusolo P, Sica S, Laurenti L, Bregante S, Van Lint MT, Dominietto A, Angelucci E, Bacigalupo A (2018) Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. Bone Marrow Transplant 53(12):1560–1567. https://doi.org/10.1038/s41409-018-0200-yCrossRefPubMedPubMedCentral

13.

Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, Santarone S, Gulbas Z, Blaise D, Messina G, Ghavamzadeh A, Malard F, Bruno B, Diez-Martin JL, Koc Y, Ciceri F, Mohty M, Nagler A (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica 102(2):401–410. https://doi.org/10.3324/haematol.2016.151779CrossRefPubMedPubMedCentral

14.

Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO (2016) Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444–455. https://doi.org/10.1111/bjh.13977CrossRefPubMedPubMedCentral

15.

Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, Van Lint MT, Koc Y, Santarone S, Forcade E, Castagna L, Polge E, Mailhol A, Ruggeri A, Mohty M, Savani BN, Nagler A (2018) Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol 93(6):769–777. https://doi.org/10.1002/ajh.25087CrossRefPubMed

16.

Pagliardini T, Harbi S, Furst S, Castagna L, Legrand F, Faucher C, Granata A, Weiller PJ, Calmels B, Lemarie C, Chabannon C, Bouabdallah R, Mokart D, Vey N, Blaise D, Devillier R (2018) Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplant 54(7):1067–1076. https://doi.org/10.1038/s41409-018-0387-yCrossRefPubMed

17.

Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, Slesarchuk OA, Bondarenko SN, Afanasyev BV (2016) Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant 22(6):1037–1042. https://doi.org/10.1016/j.bbmt.2016.03.004CrossRefPubMed

18.

Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolanos-Meade J, Hamadani M (2016) Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127(7):938–947. https://doi.org/10.1182/blood-2015-09-671834CrossRefPubMedPubMedCentral

19.

Soltermann Y, Heim D, Medinger M, Baldomero H, Halter JP, Gerull S, Arranto C, Passweg JR, Kleber M (2019) Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann Hematol 98(6):1485–1493. https://doi.org/10.1007/s00277-019-03673-3CrossRefPubMed

20.

Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U (2015) Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant 21(4):604–611. https://doi.org/10.1016/j.bbmt.2014.08.014CrossRefPubMed

21.

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M (2019) Post-transplant cyclophosphamide versus antithymocyte globulin in HLA-mismatched unrelated donors transplantation. Blood 134(11):892–899. https://doi.org/10.1182/blood.2019000487CrossRefPubMed

22.

Nykolyszyn C, Granata A, Pagliardini T, Castagna L, Harbi S, Bouabdallah R, Vey N, Fürst S, Maisano V, Legrand F, Lemarié C, Calmels B, Chabannon C, Weiller PJ, Blaise D, Devillier R (2020) Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transplant 55(2):349–355. https://doi.org/10.1038/s41409-019-0682-2CrossRefPubMed

23.

Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhauser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socie G (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855–864. https://doi.org/10.1016/s1470-2045(09)70225-6CrossRefPubMed

24.

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R (2016) Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17(2):164–173. https://doi.org/10.1016/s1470-2045(15)00462-3CrossRefPubMed

25.

Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Perez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Volp A, Ayuk F, Ruutu T, Bonifazi F (2016) Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374(1):43–53. https://doi.org/10.1056/NEJMoa1506002CrossRefPubMed

26.

Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB (2017) Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol 35(36):4003–4011. https://doi.org/10.1200/jco.2017.75.8177CrossRefPubMed

27.

Baron F, Mohty M, Blaise D, Socie G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A (2017) Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 102(2):224–234. https://doi.org/10.3324/haematol.2016.148510CrossRefPubMedPubMedCentral

28.

Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641–650. https://doi.org/10.1016/j.bbmt.2008.03.005CrossRefPubMedPubMedCentral

29.

George B, Pn N, Devasia AJ, Kulkarni U, Korula A, Lakshmi KM, Abraham A, Srivastava A, Mathews V (2018) Post-transplant cyclophosphamide as sole graft-versus-host disease prophylaxis is feasible in patients undergoing peripheral blood stem cell transplantation for severe aplastic anemia using matched sibling donors. Biol Blood Marrow Transplant 24(3):494–500. https://doi.org/10.1016/j.bbmt.2017.10.034CrossRefPubMed

30.

Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, Furukawa T, Nara M, Akashi K, Taniguchi S, Harada M, Matsuo K, Teshima T (2019) Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant 54(3):432–441. https://doi.org/10.1038/s41409-018-0279-1CrossRefPubMed

31.

Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M (2017) Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. Biol Blood Marrow Transplant 23(3):459–466. https://doi.org/10.1016/j.bbmt.2016.12.636CrossRefPubMed

32.

Du K, Hu Y, Wu K, Huang H (2013) Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transpl 27(2):E91–e100. https://doi.org/10.1111/ctr.12091CrossRef

33.

Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA (2018) Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant 54(7):1094–1106. https://doi.org/10.1038/s41409-018-0393-0CrossRefPubMed

34.

Mussetti A, Greco R, Peccatori J, Corradini P (2017) Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? Expert Rev Hematol 10(5):479–492. https://doi.org/10.1080/17474086.2017.1318054CrossRefPubMed

35.

Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L (2016) Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 53(2):90–97. https://doi.org/10.1053/j.seminhematol.2016.01.005CrossRefPubMedPubMedCentral

36.

Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, van Tol MJ, Knibbe CA, Bredius RG, Boelens JJ (2015) Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol 2(5):e194–e203. https://doi.org/10.1016/s2352-3026(15)00045-9CrossRefPubMed

37.

Zeiser R, Blazar BR (2017) Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 377(22):2167–2179. https://doi.org/10.1056/NEJMra1609337CrossRefPubMedPubMedCentral

38.

Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG (2019) Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest 129(6):2357–2373. https://doi.org/10.1172/JCI124218CrossRefPubMedPubMedCentral

39.

Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565–2579. https://doi.org/10.1056/NEJMra1703472CrossRefPubMed

Titel: Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis
verfasst von: Feiqiong Gao
Jiawei Zhang
Jianlai Hu
Liming Lin
Yang Xu
Publikationsdatum: 08.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-021-04399-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Congenital dyserythropoietic anemia types Ib, II, and III: novel variants in the CDIN1 gene and functional study of a novel variant in the KIF23 gene

ADAMTS-13–VWF axis in sickle cell disease patients

Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis

Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL

Prenatal diagnosis of familial hemophagocytic lymphohistiocytosis: morphological findings in the product of conception

Hematologic disorders associated with COVID-19: a review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin